ALT Q1 2020 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-25.1% YoY

Gross Profit

-$3M-145.7% margin

Operating Income

-$7M-330.2% margin

Net Income

-$4M-175.6% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+284.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$214,921

Balance Sheet

Total Assets

$54M

Total Liabilities

$12M

Stockholders' Equity

$42M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-25.1%
Gross Profit	-$3M	-$262,079	-1130.5%
Operating Income	-$7M	-$2M	-213.8%
Net Income	-$4M	-$2M	-85.3%